Market-Moving News for August 18th
Key takeaways
- XOS and AMLX rally on contracts and upcoming trial data, while Home Depot confirms solid Q2 earnings.
- XOS shares up 140%
- AMLX shares up 23%
- HD Q2 Adj. EPS $4.92 vs $4.73 estimate
What happened
shares surged 140% after the company announced it secured a prototype Other Transaction Agreement with the United States Air Force to develop a deployable mobile charging solution for electrified support equipment and vehicles. Amylyx Pharmaceuticals shares climbed 23% following its announcement that it will disclose the topline results of its Phase 3 LUCIDITY clinical trial of Avexitide for post‑bariatric hypoglycemia on August 18, 2026. Home Depot reported Q2 adjusted earnings per share of…
Why it matters
The XOS contract represents a significant validation and potential revenue stream from a major defense customer, while the AMLX trial results could materially influence the company’s valuation if the data are positive. Home Depot’s earnings beat reinforces confidence in the home‑improvement sector and supports the…
Short-term and longer-term
Short-term. XOS’s 140% jump signals a strong market reaction to a defense contract that could unlock future revenue; AMLX’s 23% rise reflects anticipation of Phase 3 trial data that may boost valuation; HD’s modest 2% gain…
Longer-term. XOS’s award of a prototype OT agreement indicates a credible entry into defense‑related electrification, potentially diversifying its revenue base.